Andreas Kogelnik

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(Redirected from Andy Kogelnik)
Source: www.openmedicinefoundation.org

Andreas ("Andy") M. Kogelnik, MD, PhD, is an internal medicine and infectious diseases specialist and the director of the Open Medicine Institute, Mountain View, California, US.[1] His interests are in bioinformatics and genomic medicine and is committed to the study and treatment of ME/CFS and other chronic illnesses.[1]

Education[edit | edit source]

ME/CFS Common Data Element (CDE) Project[edit | edit source]

Kogelnik is a member of the Immune Working Group of the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Common Data Element (CDE) Project, sponsored by the National Institute of Neurological Disorders and Stroke and the Centers for Disease Control and Prevention.[2]

Research publications on ME/CFS[edit | edit source]

Articles[edit | edit source]

Talks and interviews[edit | edit source]

The Open Medicine Institute, Part 1,
The Open Medicine Institute, Part 2,
The Open Medicine Institute, Part 3
Interview with Dr. Andreas Kogelnik, Part 1
Interview with Dr. Andreas Kogelnik, Part 2

References[edit | edit source]

  1. 1.0 1.1 1.2 1.3 1.4 1.5 "The Clinic". Open Medicine Institute. Retrieved April 17, 2019.
  2. "Complete Myalgic Encephalomyelitis/Chronic Fatigue Syndrome CDE Roster". NIH. Retrieved October 11, 2019.
  3. Kogelnik, AM; Loomis, K; Hoegh-Petersen, M; Rosso, F; Hischier, C; Montoya, JG. "Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue". Journal of Clinical Virology. 37: Suppl 1:S33-8. doi:10.1016/S1386-6532(06)70009-9. PMID 17276366.
  4. Knox, K.; Carrigan, D.; Simmons, G.; Teque, F.; Zhou, Y.; Hackett, J.; Qiu, X.; Luk, K.-C.; Schochetman, G.; Kogelnik, AM (July 1, 2011). "No Evidence of Murine-Like Gammaretroviruses in CFS Patients Previously Identified as XMRV-Infected". Science. 333 (6038): 94–97. doi:10.1126/science.1204963. ISSN 0036-8075.
  5. Montoya, JG; Kogelnik, AM; Bhangoo, M; Lunn, MR; Flamand, L; Merrihew, LE; Watt, T; Kubo, JT; Paik, J; Desai, M (2013), "Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome.", Journal of Medical Virology, 85 (12): 2101-9, doi:10.1002/jmv.23713, PMID 23959519
  6. Unger, Elizabeth R.; Lin, Jin-Mann S.; Tian, Hao; Natelson, Benjamin H; Lange, Gudrun; Vu, Diana; Blate, Michelle; Klimas, Nancy G.; Balbin, Elizabeth G.; Bateman, Lucinda; Allen, Ali; Lapp, Charles W.; Springs, Wendy; Kogelnik, Andreas M.; Phan, Catrina C.; Danver, Joan; Podell, Richard N.; Fitzpatrick, Trisha; Peterson, Daniel L.; Gottschalk, C. Gunnar; Rajeevan, Mangalathu S.; MCAM Study Group (2017), "Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study.", American Journal of Epidemiology, 1–10, doi:10.1093/aje/kwx029
  7. "UK Charity for Myalgic Encephalomyelitis Centre of Excellence for ME Blog". investinme.org. Retrieved July 16, 2019.
  8. "UK Charity for Myalgic Encephalomyelitis Centre of Excellence for ME Blog". investinme.org. Retrieved July 16, 2019.
  9. "UK Charity for Myalgic Encephalomyelitis Centre of Excellence for ME Blog". investinme.org. Retrieved July 16, 2019.